Why One Drug Company Held Back a Better Drug

After a stinging rebuke last week at the polls, President Trump announced that he would elevate Stephen Miller — a driving force behind some of the most polarizing policies of Mr. Trump’s second term — to chief of staff.Maggie Haberman and Jonathan Swan, White House reporters for ...  Show more

The governor-elect of Georgia is elated about her party’s victories in the South, but knows realignment is far from secure.Thoughts? Email us at theinterview@nytimes.comWatch our show on YouTube: youtube.com/@TheInterviewPodcastFor transcripts and more, visit: nytimes.com/theinte ...  Show more

Between 2006 and 2016, the number of drug patents granted in the United States doubled -- but not because there was an explosion in invention or innovation. Drug companies have learned how to game the system, accumulating patents not for new medicines but for small changes to exi ...  Show more

Gilead Sciences announced today that it will charge the U.S. government and other developed countries $390 per vial for its coronavirus-fighting drug remdesivir. That begins to answer a big question as drug companies race to find treatments and develop vaccines for the virus: How ...  Show more

Between 2006 and 2016, the number of drug patents granted in the United States doubled -- but not because there was an explosion in invention or innovation. Drug companies have learned how to game the system, accumulating patents not for new medicines but for small changes to exi ...  Show more